%0 Journal Article
%T 免疫检查点抑制剂联合疗法在晚期非小细胞肺癌中的疗效研究进展<br>Research Progress on the Efficacy of Immune Checkpoint Inhibitor Combination Therapy in Advanced Non-Small Cell Lung Cancer
%A 马普艳
%A 李春华
%A 申艳梅
%A 罗铁成
%A 闵秋霞
%A 曹玮
%J Hans Journal of Biomedicine
%P 265-272
%@ 2161-8984
%D 2025
%I Hans Publishing
%R 10.12677/hjbm.2025.152030
%X 晚期非小细胞肺癌临床治疗选择有限且获益率低。如何延长生存期、提高生活质量及控制症状成为了当前研究的热点。免疫检查点抑制剂是治疗晚期非小细胞肺癌的重要手段&#65292;但患者临床治疗的应答率低。近年来&#65292;免疫检查点抑制剂联合疗法成为了抑制肿瘤发展的新策略。深入探究药物联用以及新兴免疫疗法的联合应用&#65292;或将成为提高肿瘤免疫疗效的关键策略之一&#65292;且对提高免疫检查点抑制剂临床治疗有效率及指导临床合理用药都具有重要的理论和实践价值。因此&#65292;本综述将总结常见免疫检查点抑制剂在晚期非小细胞肺癌中的疗效研究进展。<br>The clinical treatment options for advanced non-small cell lung cancer are limited and the success rate is low. The question of how to prolong survival, improve quality of life and control symptoms is the focus of current research. Immune checkpoint inhibitors (ICIs) are important for the treatment of advanced non-small cell lung cancer (NSCLC), but the response rate to clinical treatment is low. In recent years, combination therapy with ICIs has emerged as a new strategy to inhibit tumor development. The in-depth research of drug combinations and the combination of immunotherapies will become one of the key strategies to improve the efficacy of tumor immunity, and has important theoretical and practical value for improving the clinical efficacy of ICIs and for the rational use of clinical drugs. Therefore, this review summarizes the research progress of current ICIs in NSCLC.
%K 免疫检查点抑制剂&#65292
%K 非小细胞肺癌&#65292
%K 免疫治疗<br>Immune Checkpoint Inhibitors
%K Non-Small Cell Lung Cancer
%K Immunotherapy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=107548